Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs

References

• Alzheimer’s Disease Facts and Figures. 2019. [cited 2020 Aug 5]. Available from: https://www.alz.org/alzheimers-dementia/facts-figures
   Google Scholar
• Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73–88.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Amyloid-β immunotherapy for alzheimer disease: is it now a long shot? Ann Neurol. 2019;85(3):303–315.
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181–192.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Minoshima S, Bohnen N, et al., Alzheimer’s association; society of nuclear medicine and molecular imaging; amyloid imaging taskforce. appropriate use criteria for amyloid pet: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer’s association. Alzheimers Dement. 9(1): e–1–16. 2013.
   Web of Science ®Google Scholar
• Rossini PM, Di Iorio R, Vecchio F, et al. Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signals analysis. An IFCN-sponsored panel of experts. Clin Neurophysiol. 2020;131(6):1287–1310.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Watling M, et al. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother. 2019;19(7):599–602.
   PubMed Web of Science ®Google Scholar
• NICE. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Care Excellence; 2011.
   Google Scholar
• Li DD, Zhang YH, Zhang W, et al. Meta-Analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci. 2019;13:472.
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017;60(2):401–425.
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’ s disease. J Neurol Neurosurg Psychiatr. 2002;72(2):310–314.
   PubMedGoogle Scholar
• Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–331.
   PubMed Web of Science ®Google Scholar
• Gasper MC, Ott BR, Lapane KL. Is Donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother. 2005;3(1):1–7.
   PubMedGoogle Scholar
• Zhu CW, Livote EE, Scarmeas N, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer’s disease. Alzheimers Dement. 2013;9(6):733–740.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414.
   PubMed Web of Science ®Google Scholar
• Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence based review). Report of the quality standards subcommittee of the American academy of neurology. Neurology. 2001;56(9):1154–1166.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;2017(13):325–373.
   Google Scholar
• IMS Health. White paper IMS disease insight. Alfinito P. innovative therapies innovative therapies for Alzheimer’s disease. New treatments will drive significant market. [cited 2020 Aug 5]. Available from: http://www.pharma-iq.com/pre-clinical-discovery-and-development/white-papers/ims-disease-insights-%E2%80%93-alzheimer%E2%80%99s-disease
   Google Scholar
• Qian X, Hamad B, Dias-Lalcaca G. The Alzheimer disease market. Nat Rev Drug Discov. 2015;14(10):675–676.
   PubMed Web of Science ®Google Scholar
• Panza F, Seripa D, Solfrizzi V, et al. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs. 2016;21(4):377–391.
   PubMed Web of Science ®Google Scholar
• Kandalepas PC, Sadleir KR, Eimer WA, et al. The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126(3):329–352.
   PubMed Web of Science ®Google Scholar
• Lorenzo A, Yankner BA. Amyloid fibril toxicity in Alzheimer’s disease and diabetes. Ann N Y Acad Sci. 1996;777:89–95.
   PubMed Web of Science ®Google Scholar
• He Y, Zheng MM, Ma Y, et al. Soluble oligomers and fibrillar species of amyloid β-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem Biophys Res Commun. 2012;429:125–130.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Solfrizzi V, et al. Time to test antibacterial therapy in Alzheimer’s disease. Brain. 2019;142(10):2905–2929.
   PubMedGoogle Scholar
• Eckert SH, Gaca J, Kolesova N, et al. Mitochondrial pharmacology of dimebon (latrepirdine) calls for a new look at its possible therapeutic potential in Alzheimer’s disease. Aging Dis. 2018;9(4):729–744.
   PubMed Web of Science ®Google Scholar
• Cukierman DS, Accardo E, Gomes RG, et al. Aroylhydrazones constitute a promising class of ‘metal-protein attenuating compounds’ for the treatment of Alzheimer’s disease: a proof-of-concept based on the study of the interactions between zinc (II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone. J Biol Inorg Chem. 2018;23(8):1227–1241.
   PubMed Web of Science ®Google Scholar
• Mohs RC, Shiovitz TM, Tariot PN, et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry. 2009;17(9):752–759.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Shinde A, Kambhampati RS, et al. Discovery and development of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT6) receptor antagonist for potential treatment. J Med Chem. 2017;60(5):1843–1859.
   PubMed Web of Science ®Google Scholar
• Hey JA, Yu JY, Versavel M, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57(3):315–333.
   PubMed Web of Science ®Google Scholar
• Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease. Curr Opin Mol Ther. 2010;12(2):240–247.
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.
   PubMed Web of Science ®Google Scholar
• Rauch JN, Luna G, Guzman E, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580(7803):381–385.
   PubMed Web of Science ®Google Scholar
• Seripa D, Solfrizzi V, Imbimbo BP, et al. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium. Expert Rev Neurother. 2016;16(3):259–277.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020;16(4):213–228.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Knopman DS, Jagust WJ, et al., Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12(2): 207–216. 2013.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, Panza F, Frisardi V, et al. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Discov. 2012;7(1):19–37.
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Rowe CC, Barnham KJ, et al. A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer’s disease: the PBT2-204 IMAGINE study. Alzheimers Dement. 2017;3(4):622–635.
   Google Scholar
• Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scylloinositol, in mild to moderate Alzheimer disease. Neurology. 2011;77(13):1253–1262.
   PubMed Web of Science ®Google Scholar
• Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med. 2019;380(15):1408–1420.
   PubMed Web of Science ®Google Scholar
• Henley D, Raghavan N, Sperling R, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med. 2019;380(15):1483–1485.
   PubMed Web of Science ®Google Scholar
• Willem M, Garratt AN, Novak B, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314(5799):664–666.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2019;28(11):967–975.
   PubMed Web of Science ®Google Scholar
• Sato T, Shimogaito N, Wu X, et al. Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2006;21(3):197–208.
   PubMedGoogle Scholar
• Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):206–212.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456.
   PubMed Web of Science ®Google Scholar
• Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease [published correction appears in neurology. 2019 Aug 20;93(8):371]. Neurology. 2019;92(18):e2070–e2080.
   PubMed Web of Science ®Google Scholar
• Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid secretion. J Med Chem. 2005;48(18):5705–5720.
   PubMed Web of Science ®Google Scholar
• Zanotti G, Cendron L, Folli C, et al. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors. FEBS Lett. 2013;587(15):2325–2331.
   PubMed Web of Science ®Google Scholar
• Qiang L, Guan Y, Li X, et al. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid. 2017;24(1):42–51.
   PubMed Web of Science ®Google Scholar
• Ross J, Sharma S, Winston J, et al. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double blind, placebo-controlled study. Curr Alzheimer Res. 2013;10(7):742–753.
   PubMed Web of Science ®Google Scholar
• Loconte V, Menozzi I, Ferrari A, et al. Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. J Struct Biol. 2019;208(2):165–173.
   PubMed Web of Science ®Google Scholar
• Hori Y, Takeda S, Cho H, et al. A food and drug administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease. J Biol Chem. 2015;290(4):1966–1978.
   PubMed Web of Science ®Google Scholar
• in 't Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging. 1998;19(6):607–611.
   PubMed Web of Science ®Google Scholar
• Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000;20(15):5709–5714.
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212–216.
   PubMed Web of Science ®Google Scholar
• Lleó A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med. 2004;10(10):1065–1066.
   PubMed Web of Science ®Google Scholar
• Vlad SC, Miller DR, Kowall NW, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70(19):1672–1677.
   PubMed Web of Science ®Google Scholar
• Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res. 2009;21(2):102–110.
   PubMed Web of Science ®Google Scholar
• Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev. 2012;(2):CD006378.
   PubMed Web of Science ®Google Scholar
• Ryan J, Storey E, Murray AM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020;95(3):e320-e331. pii: 10.1212/WNL.0000000000009277 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Akaishi T, Morimoto T, Shibao M, et al. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein. Neurosci Lett. 2008;444(3):280–285.
   PubMed Web of Science ®Google Scholar
• Ushikubo H, Watanabe S, Tanimoto Y, et al. 3,3ʹ,4ʹ,5,5ʹ-pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation. Neurosci Lett. 2012;513(1):51–56.
   PubMed Web of Science ®Google Scholar
• Zhang C, Griciuc A, Hudry E, et al. Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci Rep. 2018;8(1):1144.
   PubMedGoogle Scholar
• Kondo T, Imamura K, Funayama M, et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer’s disease. Cell Rep. 2017;21(8):2304–2312.
   PubMed Web of Science ®Google Scholar
• Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–919.
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nat Neurosci. 2002;5(5):452–457.
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP, et al. Anti-β-amyloid immunotherapy for Alzheimer’s disease: focus on bapineuzumab. Curr Alzheimer Res. 2011;8(8):808–817.
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Murray ED, Price BH, et al. Bapineuzumab and solanezumab for Alzheimer’s disease: is the ‘amyloid cascade hypothesis’ still alive? Expert Opin Biol Ther. 2013;13(7):1075–1084.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 370(4): 322–333. 2014.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Rev Clin Immunol. 2012;8(2):135–149.
   PubMed Web of Science ®Google Scholar
• Bouter Y, Lopez Noguerola JS, Tucholla P, et al. Aβ targets of the biosimilar antibodies of bapineuzumab, crenezumab, solanezumab in comparison to an antibody against N truncated Aβ in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol. 2015;130(5):713–729.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33(2):67–73.
   PubMed Web of Science ®Google Scholar
• Farlow M, Arnold SE, van Dyck CH, et al., Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 8(4): 261–271. 2012.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 370(4): 311–321. 2014.
   PubMed Web of Science ®Google Scholar
• Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–330.
   PubMed Web of Science ®Google Scholar
• Schwarz AJ, Sundell KL, Charil A, et al. Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer’s disease. Alzheimers Dement (N Y). 2019;5:328–337.
   PubMedGoogle Scholar
• Donohue MC, Sperling RA, Salmon DP, et al. Australian imaging, biomarkers, and lifestyle flagship study of ageing, Alzheimer’s disease neuroimaging initiative, Alzheimer’s disease cooperative study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961–970.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rentz DM, Johnson KA, et al. The A4 Study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Weigand SD, et al., An operational approach to NIA–AA criteria for preclinical Alzheimer’s disease. Ann Neurol. 71(6): 765–775. 2011.
   Web of Science ®Google Scholar
• Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8–19.
   PubMed Web of Science ®Google Scholar
• Washington University School of Medicine in St. Louis. Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates. cited 2020 Aug 5]. Available from: https://medicine.wustl.edu/news/alzheimers-diantu-trial-initial-results
   Google Scholar
• Panza F, Solfrizzi V, Imbimbo BP, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Rev Neurother. 2014;14(9):973–986.
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28:49–69.
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 69(2): 198–207. 2012.
   PubMedGoogle Scholar
• Hoffmann-La Roche Media Release. Roche provides update on gantenerumab development programme. [cited 2020 Aug 5]. Available from: http://www.roche.com/media/store/releases/med-cor-2014-12-19b.htm
   Google Scholar
• Ostrowitzki S, Lasser RA, Dorflinger E, et al., A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 9(1): 95. 2017.
   PubMedGoogle Scholar
• Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11(1):101.
   PubMed Web of Science ®Google Scholar
• Abi-Saab D, Andjelkovic M, Pross N, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the marguerite RoAD study in patients with prodromal Alzheimer’s disease (AD) after approximately 2 years of study duration. Alzheimers Dement. 2018;14(Suppl):P241.
   Google Scholar
• Bussiere T, Weinreb PH, Dunstan RW, et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-Aβ clinical antibody candidates. Neurodegener Dis. 2013;11(suppl):1.
   PubMedGoogle Scholar
• Ferrero J, Williams L, Stella H, et al. First- in-human, double- blind, placebo controlled, single-dose escalation study of aducanumab (BIIB037) in mild- to-moderate Alzheimer’s disease. Alzheimers Dement. 2016;2:169–176.
   Google Scholar
• Sevigny J, Chiao P, Bussière T, et al., The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 537(7618): 50–56. 2016.
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, O’Gorman J, Chiao P, et al. Clinical development of aducanumab, an anti-Aβ human monoclonal antibody being investigated for the treatment of early Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4(4):255–263.
   PubMed Web of Science ®Google Scholar
• Biogen/Eisai Halt phase 3 aducanumab trials 21 Mar 2019. [cited 2020 Aug 5]. Available from: https://www.alzforum.org/news/research-news/biogeneisai-halt-phase-3-aducanumab-trials
   Google Scholar
• Biogen Q1 Update. [cited 2020 Aug 5]. Available from: http://investors.biogen.com/static-files/1e8f9954-58d4-41cf-a6d7-6626338656c3
   Google Scholar
• Cure Alzheimer’s fund. biogen announces intention to file with fda for approval for new Alzheimer’s drug aducanumab – cure Alzheimer’s fund. [online]. [cited 2020 Aug 5]. Available from: https://curealz.org/news-and-events/aducanumab
   Google Scholar
• Exposure, exposure, exposure? At CTAD, aducanumab scientists make a case 13 Dec 2019. [Last accessed 2020 Aug 5]. Available from: https://www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case
   Google Scholar
• Tucker S, Möller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575–588.
   PubMed Web of Science ®Google Scholar
• Söllvander S, Nikitidou E, Gallasch L, et al. The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. J Neuroinflammation. 2018;15(1):98.
   PubMedGoogle Scholar
• Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401–a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016;8(1):14.
   PubMedGoogle Scholar
• Satlin A, Wang J, Logovinsky V, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimers Dement (N Y). 2016;2(1):1–12.
   PubMedGoogle Scholar
• Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993–999.
   PubMed Web of Science ®Google Scholar
• Osswald G BioArctic announces positive topline results of BAN2401 phase 2b at 18 months in early Alzheimer’s disease. BioArctic. [cited 2018 Jul 6].
   Google Scholar
• Lalonde R, Dumont M, Staufenbiel M, et al. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157(1):91–98.
   PubMed Web of Science ®Google Scholar
• Minkeviciene R, Rheims S, Dobszay MB, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29(11):3453–3462.
   PubMed Web of Science ®Google Scholar
• Shi JQ, Wang BR, Tian YY, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19(11):871–881.
   PubMed Web of Science ®Google Scholar
• Koh MT, Haberman RP, Foti S, et al. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010;35(4):1016–1025.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Ranasinghe KG, Beagle AJ, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Ann Neurol. 2016;80(6):858–870.
   PubMed Web of Science ®Google Scholar
• Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–466.
   PubMed Web of Science ®Google Scholar
• Bakker A, Krauss GL, Albert MS, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467–474.
   PubMed Web of Science ®Google Scholar
• Bakker A, Albert MS, Krauss G, et al. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015;7:688–698.
   PubMed Web of Science ®Google Scholar
• Musaeus CS, Shafi MM, Santarnecchi E, et al. Levetiracetam alters oscillatory connectivity in Alzheimer’s disease. J Alzheimers Dis. 2017;58(4):1065–1076.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29(10):787–803.
   PubMed Web of Science ®Google Scholar
• Hu J, Geng M, Li J, et al. Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid beta protein. J Pharmacol Sci. 2004;95(2):248–255.
   PubMed Web of Science ®Google Scholar
• Wang S, Li J, Xia W, et al. A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro. Neurol Res. 2007;29(1):96–102.
   PubMed Web of Science ®Google Scholar
• 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD). Abstract OC3; Presented November 20, 2014, Philadelphia, PA, USA.
   Google Scholar
• Fits and starts: trial results from the CTAD conference. [cited 2020 Aug 5]. Available from: https://www.alzforum.org/news/conference-coverage/fits-and-starts-trial-results-ctad-conference#Meiyu
   Google Scholar
• Green valley announces NMPA approval of oligomannate for mild to moderate Alzheimer’s disease. [cited 2020 Aug 5]. Available from: https://www.greenvalleypharma.com/En/Index/pageView/catid/48/id/28.html
   Google Scholar
• Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-based immunotherapy for Alzheimer’s disase in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014;10(3):405–419.
   PubMed Web of Science ®Google Scholar
• Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013;169(10):737–743.
   PubMed Web of Science ®Google Scholar
• Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer’s Prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–329.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292.
   PubMed Web of Science ®Google Scholar
• Struble RG, Ala T, Patrylo PR, et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer’s type? J Alzheimers Dis. 2010;22(2):393–399.
   PubMed Web of Science ®Google Scholar
• Johnson V, Stewart W, Smith DH. Traumatic brain injury and amyloid-β pathology: a link to Alzheimer’s disease? Nat Rev Neurosci. 2010;11(5):361–370.
   PubMed Web of Science ®Google Scholar
• Stein TD, Montenigro PH, Alvarez VE, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015;130(1):21–34.
   PubMed Web of Science ®Google Scholar
• Dong Y, Zhang G, Zhang B, et al. The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol. 2009;66(5):620–631.
   PubMedGoogle Scholar
• Pluta R, Furmaga-Jabłonska W, Maciejewski R, et al. Brain ischemia activates β- and γ- secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer’s disease. Mol Neurobiol. 2013;47(1):425–434.
   PubMed Web of Science ®Google Scholar
• ElAli A, Thériault P, Préfontaine P, et al. Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral β- amyloid brain entry and aggregation. Acta Neuropathol Commun. 2013;1:75.
   PubMed Web of Science ®Google Scholar
• Donovan NJ, Locascio JJ, Marshall GA, et al. Longitudinal association of amyloid β and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;175(5):530–537.
   PubMedGoogle Scholar
• Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry. 2012;169(5):523–530.
   PubMed Web of Science ®Google Scholar
• Bryson JB, Hobbs C, Parsons MJ, et al. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(1):3871–3882.
   PubMedGoogle Scholar
• Coan G, Mitchell CS. An assessment of possible neuropathology and clinical relationships in 46 sporadic amyotrophic lateral sclerosis patient autopsies. Neurodegener Dis. 2015;15(5):301–312.
   PubMed Web of Science ®Google Scholar
• Reinsfelt B, Westerlind A, Blennow K, et al. Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β. Acta Anaesthesiol Scand. 2013;57(1):82–88.
   PubMed Web of Science ®Google Scholar
• Hu Y, Shi S, Liu X, et al. Effects of heart bypass surgery on plasma Aβ40 and Aβ42 levels in infants and young children. Medicine (Baltimore). 2016;95(6):e2684.
   PubMed Web of Science ®Google Scholar
• Ooms S, Overeem S, Besse K, et al. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β- amyloid 42 in healthy middle- aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971–977.
   PubMed Web of Science ®Google Scholar
• Lucey BP, Hicks TJ, McLeland JS, et al. Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Ann Neurol. 2018;83(1):197–204.
   PubMed Web of Science ®Google Scholar
• Shokri- Kojori E, Wang GJ, Wiers CE, et al. β-amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci USA. 2018;115(17):4483–4488.
   PubMed Web of Science ®Google Scholar
• Ju YS, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain. 2017;140(8):2104–2111.
   PubMed Web of Science ®Google Scholar
• Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid- β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:118.
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Castellani RJ, et al. Amyloid- β in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007;321(3):823–829.
   PubMed Web of Science ®Google Scholar
• Kokjohn TA, Maarouf CL, Roher AE. Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement. 2012;8(6):574–583.
   PubMed Web of Science ®Google Scholar
• Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013;9(1):25–34.
   PubMed Web of Science ®Google Scholar
• Jones DT, Graff-Radford J, Lowe VJ, et al. Tau, amyloid, and cascading network failure across the Alzheimer’s disease spectrum. Cortex. 2017;97:143–159.
   PubMed Web of Science ®Google Scholar
• Herrup K. Reimagining Alzheimer’s disease - an age-based hypothesis. J Neurosci. 2010;30(50):16755–16762.
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Lee HG, Zhu X, et al. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008;67(6):523–531.
   PubMed Web of Science ®Google Scholar
• Castello MA, Soriano S. Rational heterodoxy: cholesterol reformation of the amyloid doctrine. Ageing Res Rev. 2013;12(1):282–288.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta. 2014;1842(8):1219–1231.
   PubMed Web of Science ®Google Scholar
• Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem. 2016;139(Suppl 2):237–252.
   PubMedGoogle Scholar
• Kuhn AJ, Raskatov J. Is the p3 peptide (Aβ17–40, Aβ17–42) relevant to the pathology of Alzheimer’s disease? J Alzheimers Dis. 2020;74(1):43–53.
   PubMed Web of Science ®Google Scholar
• Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. 2017;13(9):1004–1012.
   PubMed Web of Science ®Google Scholar
• Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305–2316.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316–2325.
   PubMed Web of Science ®Google Scholar
• Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19(3):271–278.
   PubMed Web of Science ®Google Scholar
• Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957–965.
   PubMed Web of Science ®Google Scholar
• Insel PS, Hansson O, Mackin RS, et al. Amyloid pathology in the progression to mild cognitive impairment. Neurobiol Aging. 2018;64:76–84.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Sperling RA, Mormino EC, Schultz AP, et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181–193.
   PubMed Web of Science ®Google Scholar
• Rabin JS, Schultz AP, Hedden T, et al. Interactive associations of vascular risk and β-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the harvard aging brain study. JAMA Neurol. 2018;75(9):1124–1131.
   PubMed Web of Science ®Google Scholar
• Vemuri P, Lesnick TG, Knopman DS, et al. Amyloid, vascular, and resilience pathways associated with cognitive aging. Ann Neurol. 2019;86(6):866–877.
   PubMed Web of Science ®Google Scholar
• Soldan A, Pettigrew C, Fagan AM, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019;92(14):e1567–e1579.
   PubMed Web of Science ®Google Scholar
• Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Mol Neurodegener. 2018;13(1):51.
   PubMedGoogle Scholar
• [No authors listed]. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;85(23):2084.
   Web of Science ®Google Scholar
• Imbimbo BP, Ippati S, Ceravolo F, et al. Perspective: is therapeutic plasma exchange a viable option for treating Alzheimer’s disease? Alzheimers Dement (N Y). 2020;6(1):e12004.
   PubMedGoogle Scholar
• Boada M, López O, Núñez L, et al. Plasma exchange for Alzheimer’s disease management by albumin replacement (AMBAR) trial: study design and progress. Alzheimers Dement. 2019;5:61–69.
   Google Scholar
• Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71–76. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512–516.
   PubMed Web of Science ®Google Scholar
• Stanciu C, Trifan A, Muzica C, et al. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin Pharmacother. 2019;20(4):379–384.
   PubMed Web of Science ®Google Scholar